SCHEMBL12065301

SCHEMBL12065301

CCOC(c1ccc(OCc2ccc(C)cc2)cc1)c1nc2cc(F)cnc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 8/20 0.42
▸ MAOB P27338 3/20 0.38
▸ MLKL Q8NB16 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ PPARG P37231 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ DHODH Q02127 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ ANO1 Q5XXA6 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ RET P07949 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ CDK7 P50613 1/20 0.33
▸ CDK5 Q00535 1/20 0.33
▸ PRKAA1 Q13131 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12066059 0.94 MAOB (0.39) FFAR1MAOBNPC1RAB9APPARG
SCHEMBL12066068 0.90 MAOB (0.40) FFAR1MAOBNPC1RAB9APPARG
SCHEMBL12065313 0.89 FFAR1 (0.42) FFAR1MAOBMLKLNPC1RAB9A
SCHEMBL14770523 0.86 FFAR1 (0.36) FFAR1MAOBNPC1RAB9ATHRB
SCHEMBL14763411 0.86 FFAR1 (0.39) FFAR1MAOB
SCHEMBL12065636 0.85 MLKL (0.42) FFAR1MAOBMLKLNPC1RAB9A
SCHEMBL14774023 0.85 MAOB (0.39) FFAR1MAOBNPC1RAB9APPARG
SCHEMBL12065296 0.83 FFAR1 (0.44) FFAR1MAOBMLKLNPC1RAB9A
SCHEMBL12066026 0.82 PDE2A (0.37) —
SCHEMBL12065283 0.80 FFAR1 (0.38) FFAR1MAOBNPC1RAB9APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US claimed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 — — EP claimed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US claimed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed
WO-2011148956-A1 FUSED IMIDAZOLE DERIVATIVE トーアエイヨー株式会社 (JP) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A FFAR1 1112/4885MAOB 2158/4885MLKL 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback